Related references
Note: Only part of the references are listed.First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade
Alecsandra Gorzo et al.
LIFE-BASEL (2022)
The current clinical landscape of personalized cancer vaccines
Hajer Fritah et al.
CANCER TREATMENT REVIEWS (2022)
Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer
Farimah Fayyaz et al.
CELL COMMUNICATION AND SIGNALING (2022)
Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
Yue Zheng et al.
DISEASE MARKERS (2022)
NK cells limit therapeutic vaccine-induced CD8+T cell immunity in a PD-L1-dependent manner
Mariana O. Diniz et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects
Siyuan Qian et al.
FRONTIERS IN IMMUNOLOGY (2022)
Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
Xin Zhang et al.
LIFE-BASEL (2022)
Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy
Zaigang Zhou et al.
JOURNAL OF CONTROLLED RELEASE (2022)
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
Andrea Cercek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Cascade two-stage tumor re-oxygenation and immune re-sensitization mediated by self-assembled albumin-sorafenib nanoparticles for enhanced photodynamic immunotherapy
Zaigang Zhou et al.
ACTA PHARMACEUTICA SINICA B (2022)
Tumor Selective Metabolic Reprogramming as a Prospective PD-L1 Depression Strategy to Reactivate Immunotherapy
Yu Liu et al.
ADVANCED MATERIALS (2022)
Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
M. Chalabi et al.
ANNALS OF ONCOLOGY (2022)
Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II
Xin Liu et al.
CLINICAL CANCER RESEARCH (2022)
Revisiting the role of CD4+T cells in cancer immunotherapy-new insights into old paradigms
Rong En Tay et al.
CANCER GENE THERAPY (2021)
KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond
Misako Nagasaka et al.
CANCER TREATMENT REVIEWS (2021)
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
Cristina Aparicio et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Nanoparticle-Mediated Delivery Systems in Photodynamic Therapy of Colorectal Cancer
Nokuphila Winifred Nompumelelo Simelane et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Intraperitoneal collagenase as a novel therapeutic approach in an experimental model of colorectal peritoneal carcinomatosis
D. Garcia-Olmo et al.
SCIENTIFIC REPORTS (2021)
Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2021)
Dendritic cell vaccine therapy for colorectal cancer
Amanda L. Wooster et al.
PHARMACOLOGICAL RESEARCH (2021)
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
Thierry Andre et al.
LANCET ONCOLOGY (2021)
Actual survival after resection of primary colorectal cancer: results from a prospective multicenter study
Inge van den Berg et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2021)
Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?
Nuttavut Sumransub et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
Federica Pecci et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)
Analyzing microsatellite instability and gene mutation in circulating cell-free DNA to monitor colorectal cancer progression
Yun Fu et al.
TRANSLATIONAL CANCER RESEARCH (2021)
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
Alexander Stein et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer
A. Guyot D'Asnieres De Salins et al.
ESMO OPEN (2021)
Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome
Christina Therkildsen et al.
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY (2021)
Current status and limitations of immunotherapy for breast cancer
Yoshihisa Tokumaru et al.
SURGERY (2020)
Advances of immune checkpoints in colorectal cancer treatment
Qinlian Jiao et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
Mark Yarchoan et al.
CANCER MEDICINE (2020)
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Maud Mayoux et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety
Yan Ge et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
A conserved dendritic-cell regulatory program limits antitumour immunity
Barbara Maier et al.
NATURE (2020)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning
Amelie Echle et al.
GASTROENTEROLOGY (2020)
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
Floris Dammeijer et al.
CANCER CELL (2020)
Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Natalia Kunst et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Masanori Oshi et al.
CANCERS (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Dan Sha et al.
CANCER DISCOVERY (2020)
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Soyoung A. Oh et al.
NATURE CANCER (2020)
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy
Samantha M. Morrissey et al.
TRENDS IN CANCER (2020)
Prognostic relevance of programmed cell death-ligand 1 expression and CD8+TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy
Tsung-Wei Chen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy
Xinyi Tu et al.
MOLECULAR CELL (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
Wenjuan Dong et al.
CANCER DISCOVERY (2019)
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
James W. Opzoomer et al.
FRONTIERS IN IMMUNOLOGY (2019)
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Francois Ghiringhelli et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer
Sumana Narayanan et al.
SCIENTIFIC REPORTS (2019)
Implementing TMB measurement in clinical practice: considerations on assay requirements
Reinhard Buettner et al.
ESMO OPEN (2019)
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
Wenxiao Jia et al.
CANCER BIOLOGY & MEDICINE (2019)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Genevieve P. Hartley et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Heating it up: Oncolytic viruses make tumors hot' and suitable for checkpoint blockade immunotherapies
Shashi Gujar et al.
ONCOIMMUNOLOGY (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
CAR T-cell therapy of solid tumors
Carmen S. M. Yong et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Chengcheng Zhang et al.
MOLECULAR THERAPY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Petros Fessas et al.
SEMINARS IN ONCOLOGY (2017)
Hypermutation and microsatellite instability in gastrointestinal cancers
Kizuki Yuza et al.
ONCOTARGET (2017)
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
Jan Willem Kleinovink et al.
ONCOIMMUNOLOGY (2017)
Is Ep-CAM Expression a Diagnostic and Prognostic Biomarker for Colorectal Cancer? A Systematic Meta-Analysis
Susu Han et al.
EBIOMEDICINE (2017)
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis
Markus Hecht et al.
EUROPEAN JOURNAL OF CANCER (2016)
Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients.
Neil Howard Segal et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Christine E. Brown et al.
CLINICAL CANCER RESEARCH (2015)
Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer
Soo Young Lee et al.
MEDICINE (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
Ayelet Sivan et al.
SCIENCE (2015)
Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC)
Leonard Christopher Schmeel et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation
D. V. Chan et al.
GENES AND IMMUNITY (2014)
Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer-A Phase I-II Study
Janos Hunyadi et al.
PATHOLOGY & ONCOLOGY RESEARCH (2014)
Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Gastric and Colorectal Cancer Patients
Daiqing Gao et al.
PLOS ONE (2014)
Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy
Hui Zhu et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Retrospective Comparative Study of the Effects of Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Immunotherapy with that of Chemotherapy Alone and in Combination for Colorectal Cancer
Jingxiu Niu et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen
T Itoh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
L Fong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
